Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. MarketScreener Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
04/12/2021 04/13/2021 04/14/2021 04/15/2021 04/16/2021 Date
7225(c) 7167(c) 7271(c) 7400(c) 7380(c) Last
1 338 070 1 581 490 1 789 183 2 424 504 2 536 841 Volume
-0.85% -0.80% +1.45% +1.77% -0.27% Change
More quotes
Financials (USD)
Sales 2021 30 805 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Sales 2022 35 117 M - -
Net income 2022 6 489 M - -
Net Debt 2022 9 676 M - -
P/E ratio 2022 18,9x
Yield 2022 2,89%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (97.3%). Net sales break down by treatment area between oncology (41.9%), cardiovascular, renal and metabolic diseases (27.4%), respiratory and autoimmune diseases (20.7%), and other (10%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); -... 
Sector
Pharmaceuticals
Calendar
04/30Earnings Release
More about the company
Notations Surperformance© of AstraZeneca PLC
Trading Rating : Investor Rating :
More Ratings
All news about ASTRAZENECA PLC
04/16ASTRAZENECA  : Quebec to deploy sound trucks in Montreal to announce mobile vacc..
AQ
04/16ASTRAZENECA  : Doctors say lowering age cutoff for AstraZeneca vaccine makes sen..
AQ
04/16Consumer Cos Climb On Reopening Optimism -- Consumer Roundup
DJ
04/16Health Care Up After Strong Start to Earnings Season -- Health Care Roundup
DJ
04/16Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.
DJ
04/16No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cas..
DJ
04/16ASTRAZENECA  : German's IDT to make 10M AstraZeneca vaccine doses in 2021
AQ
04/16ASTRAZENECA  : Covid-19 - Lagos, Kano Lead As Nigeria Vaccinates Over 1m Persons
AQ
04/16MARKET CHATTER : Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Produ..
MT
04/16ASTRAZENECA  : Australia's Medicine Watchdog Links Woman's Death To AstraZeneca ..
MT
04/16THE LATEST : Australia reports death after AstraZeneca shot
AQ
04/16ASTRAZENECA  : Secures US Nod For $39 Billion Alexion Deal
MT
04/16EU to Focus on mRNA-based COVID-19 Jabs, Likely to Ditch AstraZeneca, Johnson..
MT
04/16ASTRAZENECA  : CEO Says Borders Need To Open To Keep Sharing Vaccines Through CO..
MT
04/16ASTRAZENECA  : Indian vaccine maker Serum Institute appeals to Biden to lift emb..
RE
More news
News in other languages on ASTRAZENECA PLC
03:38aUnternehmen wollen Impfaktion in Deutschland beschleunigen
04/16CORONAVIRUS : le seuil des 3 millions de morts imminent, course à la vaccination
04/16En France, l'épidémie se stabilise à un niveau élevé, prudence sur le cap du ..
04/16Coronavirus-Quasiment tous les résidents d'Ehpad vaccinés en France, dit Véra..
04/16++ Analysen des Tages von Dow Jones Newswires (16.04.2021) +++
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC0.76%133 897
JOHNSON & JOHNSON3.09%422 260
ROCHE HOLDING AG0.16%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-5.29%194 049